Related Experiment Video
Updated: Jan 14, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting
Seohyeon Park1, Sang Min Lee1, Kwan Cheol Pak1
1Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Purpose:
rhIL-7-hyFc (Efineptakin alfa) is a novel, long-acting recombinant human interleukin-7 developed to enhance immune responses by correcting T-cell deficiencies through increased lymphocyte counts. This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model to support selection of the recommended Phase 2 dose (RP2D) through optimization of dosing regimens.
Patients And Methods:
Serum rhIL-7-hyFc concentrations and absolute lymphocyte counts (ALC) were collected from 35 patients with solid tumors enrolled in a Phase Ib clinical trial (NCT03478995), who received multiple intramuscular administrations of rhIL-7-hyFc at doses ranging from 0.06 to 1.7 mg/kg every 3 or 6 weeks. A sequential mixed-effects PK-PD model was developed using NONMEM® (version 7.4.3) based on individual PK parameters. Monte Carlo simulations with extended dosing intervals up to 12 weeks were conducted to explore serum concentration profiles, ALC dynamics over time, and exposure-response relationships.
Results:
The PK data were best described by a two-compartment model with first-order absorption from two depot compartments, and inter-occasional variability in clearance was incorporated in the final model. To account for the time-delayed response, the PD model utilized a series of transit compartments representing lymphocyte maturation. The stimulatory effect of rhIL-7-hyFc on progenitor cell proliferation was described using a simple maximum effect model. The estimated half-maximum effective concentration (EC50) was 0.066 ng/mL, indicating a high potency in increasing serum lymphocyte levels. Monte-Carlo simulation based on the final PK-PD model showed a dose-dependent increase in ALC. A dose range of 0.6-1.2 mg/kg administered at intervals of 6 to 12 weeks was suggested as feasible for the RP2D in further clinical trials.
Conclusion:
A population PK-PD modeling and simulation results demonstrated a strong exposure-response relationship for ALC across dosing intervals, underscoring the mechanism-based therapeutic potential of rhIL-7-hyFc in cancer immunotherapy.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:12Analysis of Population Pharmacokinetic Data
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:14Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...